首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1471973

腫瘤生物相似藥市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按藥物類別、癌症類型和配銷通路

Oncology Biosimilars Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Cancer Type, and Distribution Channel

出版日期: 2024年03月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

2023年腫瘤生物相似藥市場價值為94.6億美元，預計到2031年將達到247.1億美元；預計 2023 年至 2031 年複合年成長率為 12.8%。

推動市場成長的關鍵因素是癌症發生率的激增，包括肺癌、大腸癌和乳癌；生物相似藥的成本效益；腫瘤生物相似藥的核准量增加。然而，生物相似藥產品製造的高成本參與和複雜性阻礙了腫瘤生物相似藥市場的成長

腫瘤生物相似藥的市場趨勢：

合資企業等合作模式可以幫助生物相似藥製造商保持競爭力。透過與其他公司合作，他們可以快速有效地開發產品、獲得資金並贏得臨床醫生和患者的信任。合作還可以提供對現有製造設施的訪問，長期利益包括輕鬆訪問未來的生產項目和早期市場滲透。以下是近期在腫瘤生物相似藥市場上備受矚目的合作的一些實例：

2023年7月，三星生物製品公司與輝瑞公司簽署了策略合作夥伴協議，以實現輝瑞公司多產品組合的長期商業化生產。根據該協議，三星生物製品公司將為輝瑞提供額外的能力，用於大規模生產涵蓋腫瘤學、發炎和免疫學的多產品生物相似藥組合。

2022年3月，Cipla Medpro連同印度Cipla Limited的全資子公司與全球生物技術公司mAbxience簽訂合作協議，向南非提供腫瘤和呼吸系統相關生物相似藥。該夥伴關係旨在確保該地區公正地獲得負擔得起的救生藥物。

因此，生物相似藥製造商之間的合作和臨床試驗預計將在未來幾年帶來新的腫瘤生物相似藥市場趨勢。

腫瘤生物相似藥：細分市場概述

腫瘤生物相似藥根據藥物類別、癌症類型和配銷通路進行細分。

依藥物類別，市場分為單株抗體、粒細胞集落刺激因子和紅血球生成促效劑。 2023年，單株抗體細分市場佔最大市場佔有率，預計2023年至2031年複合年成長率最高。。肺癌細分市場在 2023 年佔據最大的腫瘤生物相似藥市場佔有率，預計 2023 年至 2031 年複合年成長率最高。 2023 年，醫院藥局領域佔據最大的市場佔有率，預計 2023 年至 2031 年複合年成長率最高。

全球腫瘤生物相似藥報告的範圍涵蓋北美（美國、加拿大和墨西哥）、歐洲（德國、法國、義大利、英國、西班牙和歐洲其他地區）、亞太地區（中國、日本、印度、澳洲、韓國和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國以及中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地區）。 2023 年，北美佔據了腫瘤生物相似藥的主要佔有率，其次是歐洲；亞太地區的市場在預測期內以最高的複合年成長率成長。這歸因於新興市場醫療保健基礎設施的發展、醫療保健支出的增加、利潤豐厚的報銷政策以及該地區越來越重視更好的患者治療結果。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 13 章：腫瘤生物相似藥市場 - 主要公司概況

Biocon
Celltrion Inc
Samsung Bioepis
Amgen Inc
Coherus BioSciences
Pfizer Inc
Sandoz International GmbH (A Novartis Division)
Teva Pharmaceutical Industries Ltd.
Lilly
BIOCAD

第 14 章：附錄

簡介目錄

Product Code: TIPRE00002766

The oncology biosimilars market was valued at US$ 9.46 billion in 2023 and is anticipated to reach US$ 24.71 billion by 2031; it is projected to register a CAGR of 12.8% from 2023 to 2031.

Key factors driving the market growth are the surge in incidences of cancers, including lung cancer, colorectal cancer, and breast cancer; the cost-effectiveness of biosimilar drugs; and a rise in the approvals of oncology biosimilars. However, high-cost involvement and complexities in biosimilar product manufacturing hamper the oncology biosimilars market growth

Market Trends of the Oncology Biosimilars:

Collaboration models such as joint ventures can help biosimilar medicine manufacturers stay competitive. By collaborating with other companies, they can develop products quickly and effectively, access funding, and gain clinician and patient confidence. Collaboration can also provide access to established manufacturing facilities, and long-term benefits include easy access to future production projects and early market penetration. A few instances of recent, high-profile collaborations in the oncology biosimilars market are given below:

In July 2023, Samsung Biologics and Pfizer signed a strategic partnership agreement for the long-term commercial manufacturing of Pfizer's multi-product portfolio. Under this agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilar portfolio covering oncology, inflammation, and immunology.

In March 2022, Cipla Medpro, along with the wholly-owned subsidiary of Cipla Limited in India, entered into a partnership agreement with mAbxience, the global biotechnology company, to provide oncology and respiratory-related biosimilars to South Africa. The partnership is aimed to ensure unbiased access to affordable, life-saving medication in the region.

Therefore, the collaborations among manufacturers for biosimilars and clinical trials are expected to bring new oncology biosimilars market trends in the coming years.

Oncology Biosimilars: Segmental Overview

The oncology biosimilars is segmented on the basis of drug class, cancer type, and distribution channel.

The market, by drug class, is segmented into monoclonal antibodies, granulocyte colony-stimulating factor, and erythropoiesis-stimulating agents. In 2023, the monoclonal antibodies segment held the largest share of the market and is anticipated to register the highest CAGR from 2023 to 2031. The market, based on cancer type, is categorized into lung cancer, colorectal cancer, cervical cancer, breast cancer, stomach cancer, brain cancer, and others. The lung cancer segment held the largest oncology biosimilars market share in 2023 and is projected to register the highest CAGR from 2023 to 2031. The oncology biosimilars market is segmented based on distribution channels into hospital pharmacies, retail pharmacies, and online pharmacies. In 2023, the hospital pharmacy segment held the largest market share and is expected to register the highest CAGR from 2023 to 2031.Oncology biosimilars: Geographical Overview

The scope of the global oncology biosimilars report entails North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America held a major oncology biosimilars share in 2023, followed by Europe; the market in Asia Pacific region is growing with the highest CAGR during the forecast period. This is attributed to developing healthcare infrastructure in emerging markets, rising healthcare expenditure, lucrative reimbursement policies, and increasing emphasis on better patient outcomes in the region.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Oncology Biosimilars Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Oncology Biosimilars Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Oncology Biosimilars Market - Global Market Analysis

6.1 Oncology Biosimilars - Global Market Overview
6.2 Oncology Biosimilars - Global Market and Forecast to 2031

7. Oncology Biosimilars Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

7.1 Overview
7.2 Monoclonal Antibodies
7.3 Erythropoiesis-Stimulating Agents
7.4 Granulocyte Colony-Stimulating Factor (G-CSF)

8. Oncology Biosimilars Market - Revenue Analysis (USD Million) - By Cancer Type, 2021-2031

8.1 Overview
8.2 Colorectal Cancer
8.3 Cervical Cancer
8.4 Breast Cancer
8.5 Supportive Care
8.6 Lymphoma
8.7 Others

9. Oncology Biosimilars Market - Revenue Analysis (USD Million) - By Distribution Channel , 2021-2031

9.1 Overview
9.2 Hospital Pharmacy
9.3 Retail Pharmacy
9.4 Online Pharmacy

10. Oncology Biosimilars Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

10.1 North America
- 10.1.1 North America Oncology Biosimilars Market Overview
- 10.1.2 North America Oncology Biosimilars Market Revenue and Forecasts to 2031
- 10.1.3 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Drug Class
- 10.1.4 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Cancer Type
- 10.1.5 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Distribution Channel
- 10.1.6 North America Oncology Biosimilars Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Oncology Biosimilars Market
    - 10.1.6.1.1 United States Oncology Biosimilars Market, by Drug Class
    - 10.1.6.1.2 United States Oncology Biosimilars Market, by Cancer Type
    - 10.1.6.1.3 United States Oncology Biosimilars Market, by Distribution Channel
  - 10.1.6.2 Canada Oncology Biosimilars Market
    - 10.1.6.2.1 Canada Oncology Biosimilars Market, by Drug Class
    - 10.1.6.2.2 Canada Oncology Biosimilars Market, by Cancer Type
    - 10.1.6.2.3 Canada Oncology Biosimilars Market, by Distribution Channel
  - 10.1.6.3 Mexico Oncology Biosimilars Market
    - 10.1.6.3.1 Mexico Oncology Biosimilars Market, by Drug Class
    - 10.1.6.3.2 Mexico Oncology Biosimilars Market, by Cancer Type
    - 10.1.6.3.3 Mexico Oncology Biosimilars Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Oncology Biosimilars Market - Key Company Profiles

13.1 Biocon
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments

Note - Similar information would be provided for below list of companies